Association of polymorphisms within the transforming growth factor‐β1 gene with diabetic nephropathy and serum cholesterol and triglyceride concentrations

Abstract

The 869 T > C and 915 G > C polymorphisms within the TGF-β1 gene were associated with DN+. Lower cholesterol and triglycerides levels were observed in TT homozygotes for the 869 T > C polymorphism. The TGF-β1 869 T allele seems to confer protection against DN+.

Gene polymorphism of transforming growth factor-β1 in Egyptian patients with type 2 diabetes and diabetic nephropathy

“…While, significant associations were reported in Chinese [23], Caucasians Polish [22], and Mexicans [42], insignificant associations were reported in Asian Indians [43] and in Japanese [44]. Although the present study has no CC genotypes among selected DN patients, the significant increase in TC genotype in DN þ patients is in accordance with the meta-analysis study of Jia et al [45] on TGF-b1 T869C (codon 10) polymorphism.…”

Association of Transforming Growth Factor Beta-1 (TGF-β1) Genetic Variation with Type 2 Diabetes and End Stage Renal Disease in Two Large Population Samples from North India

“…Similar trends were reported by a study on an Egyptian population where frequency of C-allele was higher in cases (both total T2D and T2D with ESRD) as compared to controls, and the TC genotype was providing 2-2.7-fold risk towards T2D and ESRD development (El-Sherbini et al, 2013). TGF-b1 g.869T > C polymorphism was observed to provide risk towards DN in Mexican (Valladares-salgado et al, 2010) and Chinese populations (Wong et al, 2003) and towards ESRD in a North Indian population (Mittal and Manchanda, 2007). Contrarily, reports on German and Spanish populations concluded that 869T allele rather than C allele was associated with ESRD susceptibility (Babel et al, 2006;Coll et al, 2004).…”

“…The present report is the first study conducted in the population of Punjab and Jammu and Kashmir evaluating the association of these polymorphisms with the risk of developing ESRD in T2D patients. Most of the previously reported studies have compared T2D and DN with each other rather with healthy controls, which can give inconclusive association and moreover, the DN cases included were of all stages (from glomerular hyperfiltration to ESRD) ( Valladares- Salgado et al, 2010). So the present study enrolled only the last stage DN cases with ESRD and compared them with both T2D and healthy controls to get irrefutable results.…”

“…Moreover, there is a paucity of studies that have compared the role of these polymorphisms in T2D and DN. Most recent studies have investigated the effect of haplotypes and diplotypes in order to obtain a more comprehensive analysis of the role of polymorphisms in the susceptibility to T2D and DN (El-Sherbini et al, 2013;Valladares-Salgado et al, 2010). The joint effect of TGF-b1 (869 and -509) polymorphisms towards T2D and DN has also not yet been studied.…”

Association of transforming growth factor-β1 polymorphisms with the risk of chronic kidney diseases

“…Valladares-Salgado et al 29 reported that TT genotype carriers of +869T/C polymorphism had lower cholesterol and triglycerides levels, and T allele carriers of +869 T/C polymorphism confer protection against diabetic nephropathy. Kowalewska-Pietrzak et al 30 reported that TT genotype carriers of À509 T/C polymorphism was a risk factor for renal scarring in primary vesicoureteral reflux (VUR), and was also associated with susceptibility to congenital uropathy.…”